by OTMS Staff | Jul 21, 2026 | PatentVest Pulse
PatentVest Pulse — What Is OpenAI Actually Patenting? PatentVest Pulse What Is OpenAI Actually Patenting? A PatentVest Pulse analysis of OpenAI’s patent portfolio July 2026 OpenAI's patents tell a story that goes far beyond ChatGPT. Rather than protecting the...
by OTMS Staff | Jul 1, 2026 | Legal Reports
PatentVest Pulse Article | 2026 | Written by: Michael Ohrenberger Why Patent Prosecution Is Ready for AI Artificial intelligence is transforming nearly every professional service industry. In the legal sector, however, not all practice areas are equally positioned to...
by OTMS Staff | Jun 26, 2026 | PatentVest Pulse
PatentVest Pulse — The Crossover PatentVest Pulse The Crossover How FGF21 Became the Cardiometabolic Layer Beneath GLP-1 Beyond GLP-1 Series, Report #6 of 12 | June 2026 Key Takeaways The next $10.7 billion opportunity isn't another GLP-1.Three pharmaceutical...
by OTMS Staff | Jun 2, 2026 | PatentVest Pulse
PatentVest Pulse — The Muscle ProblemPATENTVEST PULSEThe Muscle Problem: How Myostatin Could Expand the GLP-1 OpportunityBeyond GLP-1 Series, Report #5 of 12 | June 2026 Key Takeaways The next obesity opportunity may not be another GLP-1. Twenty programs are building...
by OTMS Staff | Apr 23, 2026 | PatentVest Pulse, Uncategorized
PatentVest Pulse — The Triple-Agonist RacePatentVest PulseThe Triple-Agonist RaceRetatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market.April 2026Ozempic and Wegovy built a $50B market with 15% weight loss. Mounjaro and Zepbound...
Recent Comments